Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 Photoimmunotherapy vs SOC in Recurrent HNSCC
NCT03769506Phase 3Active, not recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- May 2019
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Light/Condition-Responsive Prodrugs
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of cetuximab sarotalocan sodium in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Rakuten Medical, Inc. Primary endpoints: Progression-Free Survival at 24 months and Overall Survival at 24 months. Started May 2019; status: active, not recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03769506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769506.